Literature DB >> 29401099

Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Jennifer H Aldrink1, Burton Appel2, Joel A Kaplan3, Robert E Hutchison4, Cindy L Schwartz5, Kara M Kelly6, Kathleen McCarten7, Peter F Ehrlich8.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29401099      PMCID： PMC5866194          DOI： 10.1097/MPH.0000000000001107

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


× No keyword cloud information.
  10 in total

1.  Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.

Authors:  S Bodis; M D Kraus; G Pinkus; B Silver; M E Kadin; G P Canellos; L N Shulman; N J Tarbell; P M Mauch
Journal:  J Clin Oncol       Date:  1997-09       Impact factor: 44.544

2.  Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.

Authors:  Irene Biasoli; Aspasia Stamatoullas; Véronique Meignin; Alain Delmer; Oumedaly Reman; Franck Morschhauser; Bertrand Coiffier; André Bosly; Marine Diviné; Pauline Brice
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

Review 3.  Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.

Authors:  Ananth Shankar; Stephen Daw
Journal:  Br J Haematol       Date:  2012-09-21       Impact factor: 6.998

4.  Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.

Authors:  V Diehl; M Sextro; J Franklin; M L Hansmann; N Harris; E Jaffe; S Poppema; M Harris; K Franssila; J van Krieken; T Marafioti; I Anagnostopoulos; H Stein
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

5.  Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents.

Authors:  Sharon B Murphy; Elaine R Morgan; Howard M Katzenstein; Morris Kletzel
Journal:  J Pediatr Hematol Oncol       Date:  2003-09       Impact factor: 1.289

6.  Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology.

Authors:  B Pellegrino; M J Terrier-Lacombe; O Oberlin; T Leblanc; Y Perel; Y Bertrand; C Beard; C Edan; C Schmitt; D Plantaz; H Pacquement; J P Vannier; C Lambilliote; G Couillault; A Babin-Boilletot; I Thuret; F Demeocq; G Leverger; G Delsol; J Landman-Parker
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

7.  Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz
Journal:  J Clin Oncol       Date:  2016-05-16       Impact factor: 44.544

8.  Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases.

Authors:  V I Pappa; A J Norton; R K Gupta; A M Wilson; A Z Rohatiner; T A Lister
Journal:  Ann Oncol       Date:  1995-07       Impact factor: 32.976

9.  Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.

Authors:  Christine Mauz-Körholz; Stephanie Gorde-Grosjean; Dirk Hasenclever; Ananth Shankar; Wolfgang Dörffel; W Hamish Wallace; Günther Schellong; Alain Robert; Dieter Körholz; Odile Oberlin; Georgina W Hall; Judith Landman-Parker
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

10.  Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.

Authors:  Lucia Nogová; Thorsten Reineke; Corinne Brillant; Michal Sieniawski; Thomas Rüdiger; Andreas Josting; Henning Bredenfeld; Roman Skripnitchenko; Rolf-Peter Müller; Hans-Konrad Müller-Hermelink; Volker Diehl; Andreas Engert
Journal:  J Clin Oncol       Date:  2007-12-17       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.